ArticleJournal of the American Society of Nephrology : JASN2014
Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer.
Article in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Prognostic role of galectins expression in patients with hepatic cancer: A meta-analysis.Medicine · 2020Pooled it
- Pooling analysis reveals that galectin-1 is a reliable prognostic biomarker in various cancers.Journal of cellular physiology · 2019Pooled it
- Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.Oncotarget · 2016Pooled it
- A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.Drug design, development and therapy · 2015Pooled it
- Clinicopathological significance of CXCR4 in non-small cell lung cancer.Drug design, development and therapy · 2015Pooled it
- Integrating GlycoSHIELD Modeling and DNA-PAINT SMLM to Map the Glycosylation-Dependent Distribution of the Na,K-ATPase.The Journal of membrane biology · 2026Article
- Spatial transcriptomics reveals injury-responsive compartments and coordinated immune-fibrotic signaling in ANCA-associated renal vasculitis.Frontiers in immunology · 2026Article
- LGALS3BP: A Potential Prognostic Biomarker Influencing Antitumor Immunity in Triple-negative Breast Cancer.Current medicinal chemistry · 2025Article
- Intracellular galectin interactions in health and disease.Seminars in immunopathology · 2024Review
- Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma.Biomedicines · 2024Article
- Galectin‑1 binds GRP78 to promote the proliferation and metastasis of gastric cancer.International journal of oncology · 2022Article
- Galectin-1 as a predictive biomarker in ovarian cancer.Journal of ovarian research · 2021Article
- Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.Nature communications · 2021Article
- Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.Neuro-oncology · 2019Article
- Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway.American journal of translational research · 2019Article
- Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.Journal of cellular and molecular medicine · 2018Article
- Clinicopathological significance of galectin-1 expression and percentage of galectin-1-expressing T cells in clear-cell renal cell carcinoma.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018Article
- Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.Journal of experimental & clinical cancer research : CR · 2018Article
- Galectins as Molecular Targets for Therapeutic Intervention.International journal of molecular sciences · 2018Review
- Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis.Cancer cell international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectin-1, a β-galactoside-binding lectin, is involved in many physiologic and pathologic processes, including cell adhesion, differentiation, angiogenesis, and tumor progression. However, the role of galectin-1 in kidney cancer remains elusive. This study evaluated the role of galectin-1 in the progression and clinical prognosis of renal cell carcinoma. We found significant overexpression of galectin-1 in both kidney cancer cell lines and metastatic tissue specimens from patients with renal cell carcinoma. Knockdown of galectin-1 gene expression in renal cancer cell lines reduced cell invasion, clonogenic ability, and epithelial-mesenchymal transition in vitro; reduced tumor outgrowth in vivo; and inhibited the angiogenesis-inducing activity of these cells in vitro and in vivo. Galectin-1 knockdown decreased CXCR4 expression levels in kidney cancer cells, and restoration of CXCR4 expression in galectin-1-silenced cells rescued cell motility and clonogenic ability. Additional studies suggested that galectin-1 induced CXCR4 expression through activation of nuclear factor-κB (NF-κB). Analysis of patient specimens confirmed the clinical significance and positive correlation between galectin-1 and CXCR4 expression levels and revealed concomitant overexpression of galectin-1 and CXCR4 associated adversely with overall and disease-free survival. Our findings suggest that galectin-1 promotes tumor progression through upregulation of CXCR4 via NF-κB. The coordinated upregulation of galectin-1 and CXCR4 may be a novel prognostic factor for survival in patients with renal cell carcinoma and the galectin-1-CXCR4 axis may serve as a therapeutic target in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.